本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2006/4/141 分钟阅读
Guidance for Industry on Exocrine Pancreatic Insufficiency Drug Products-Submitting New Drug Applications; Availability
本地自动翻译 · 来源原始语言
摘要
The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled "Exocrine Pancreatic Insufficiency Drug Products--Submitting NDAs." This guidance is intended to assist manufacturers of exocrine pancreatic insufficiency drug products in preparing and submitting documentation to meet new drug application (NDA) requirements for the drug products.
来源原始语言: Federal Register — Food and Drug Administration打开原始公告 →